Natalie Lam
- Position: Visiting Research Assistant
- Areas of expertise: Systematic review; trial coordination
- Email: N.E.Lam@leeds.ac.uk
- Location: Temple Bank House, Bradford Institute for Health Research
Profile
Natalie has joined the Academic Unit of Elderly Care and Rehabilitation in August 2018 as a Research Assistant.
Natalie studied nutrition and worked in clinical settings for her placement in her first degree. However, she spent eight years working in the Civil Service, while studying PG Diploma in Health Research and Master of Public Health in the University of Leeds.
In 2015, she had a career change. She worked as Clinical Research Officer in South West Yorkshire Partnership NHS Foundation Trust. Following her family’s move to Wiltshire in 2016, she worked as Data Manager in the Clinical Trials Service Unit in the University of Oxford. She mainly worked in randomised control trials in dementia and late-onset psychosis, while helping in coordinating follow-ups for large-scale trials in cardiovascular diseases.
Back to Yorkshire, Natalie is now assisting in the systemic reviews in the Academic Unit of Elderly Care and Rehabilitation, Bradford Institute for Health Research.
Research interests
Research collaboration:
Howard, R., Cort, E., Bradley, R., Harper, E., Kelly, L., Bentham, P., Ritchie, C., Reeves, S., Fawzi, W., Livingston, G. and Sommerlad, A., 2018. Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trial. The Lancet Psychiatry, 5(7), pp.553-563.
ASCEND Study Collaborative Group, 2018. Effects of n− 3 Fatty Acid Supplements in Diabetes Mellitus. New England Journal of Medicine.
ASCEND Study Collaborative Group, 2018. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. New England Journal of Medicine.
Landray, M.J., Group, R.C., Bowman, L., Chen, F., Sammons, E., Hopewell, J.C., Wallendszus, K., Stevens, W., Valdes-Marquez, E., Wiviott, S. and Cannon, C.P., 2017. Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics. American heart journal, 187, pp.182-190.
Qualifications
- Master of Public Health, University of Leeds (2014), Passed with Merit
- PG Diploma in Health Research, University of Leeds (2009), Passed with Merit
- BSc (Hons) Nutritional Studies, Leeds Metropolitan University (2005), Second Honours
Research groups and institutes
- Leeds Institute of Health Sciences